Literature DB >> 29527635

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Stephanie Strobl1, Kerstin Wimmer1, Ruth Exner1, Yelena Devyatko1, Michael Bolliger1, Florian Fitzal1, Michael Gnant2.   

Abstract

OPINION STATEMENT: Bone health and breast cancer are two connected subjects, because breast cancer patients have a higher prevalence of osteopenia/osteoporosis and reduced bone health parameters than healthy woman of the same age. Therefore, the positive effect of adjuvant bisphosphonate therapy plays an important role in breast cancer treatment. Several randomized trials have studied bisphosphonates in the adjuvant setting in postmenopausal woman and demonstrated their potential to prevent treatment-induced bone loss. The prevention of fractures and the subsequent preservation of patients' quality of life are important arguments for the use of adjuvant bisphosphonates in postmenopausal breast cancer patients. In addition, trials of adjuvant bone-targeted agents showed a reduction of recurrences in and outside bone and an improved outcome in patients treated with bisphosphonates.

Entities:  

Keywords:  Adjuvant; Antitumor effect; Bone loss; Bone metastasis; Postmenopausal

Mesh：

Substances：

Year:  2018        PMID： 29527635     DOI： 10.1007/s11864-018-0535-z

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  60 in total

Review 1.  Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Sukhbinder Dhesy-Thind; Glenn G Fletcher; Phillip S Blanchette; Mark J Clemons; Melissa S Dillmon; Elizabeth S Frank; Sonal Gandhi; Rasna Gupta; Mihaela Mates; Beverly Moy; Ted Vandenberg; Catherine H Van Poznak
Journal:  J Clin Oncol       Date:  2017-03-06       Impact factor: 44.544

2.  Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics.

Authors:  B Naume; E Borgen; G Kvalheim; R Kåresen; H Qvist; T Sauer; T Kumar; J M Nesland
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

Review 4.  Dosing of zoledronic acid throughout the treatment continuum in breast cancer.

Authors:  Peyman Hadji; Michael Gnant; Matti Aapro; Allan Lipton; Robert Coleman
Journal:  Crit Rev Oncol Hematol       Date:  2010-09-16       Impact factor: 6.312

5.  The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.

Authors:  Joyce A Cramer; Niall O Lynch; Anne-Francoise Gaudin; Mel Walker; Warren Cowell
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

6.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

Authors:  R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred
Journal:  Ann Oncol       Date:  2012-10-09       Impact factor: 32.976

7.  Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.

Authors:  Robert Coleman; David Cameron; David Dodwell; Richard Bell; Caroline Wilson; Emma Rathbone; Maccon Keane; Miguel Gil; Roger Burkinshaw; Robert Grieve; Peter Barrett-Lee; Diana Ritchie; Victoria Liversedge; Samantha Hinsley; Helen Marshall
Journal:  Lancet Oncol       Date:  2014-07-15       Impact factor: 41.316

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.

Authors:  Penelope D Ottewell; Ning Wang; Hannah K Brown; Kimberly J Reeves; C Anne Fowles; Peter I Croucher; Colby L Eaton; Ingunn Holen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

10.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].

Authors:  Trevor Powles; Alexander Paterson; Eugene McCloskey; Phil Schein; Bobbi Scheffler; Alwynne Tidy; Sue Ashley; Ian Smith; Lars Ottestad; John Kanis
Journal:  Breast Cancer Res       Date:  2006-03-15       Impact factor: 6.466
View more
  3 in total

Review 1.  Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer.

Authors:  Stella D'Oronzo; Erica Silvestris; Angelo Paradiso; Mauro Cives; Marco Tucci
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

2.  Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).

Authors:  Stefanie de Groot; Hanno Pijl; Ayoub Charehbili; Saskia van de Ven; Vincent T H B M Smit; Elma Meershoek-Klein Kranenbarg; Joan B Heijns; Laurence J C van Warmerdam; Lonneke W Kessels; M Wouter Dercksen; Manon J A E Pepels; Hanneke W M van Laarhoven; Birgit E P J Vriens; Hein Putter; Marta Fiocco; Gerrit-Jan Liefers; Jacobus J M van der Hoeven; Johan W R Nortier; Judith R Kroep
Journal:  Breast Cancer Res       Date:  2019-08-28       Impact factor: 6.466

3.  From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors.

Authors:  Leonor Vasconcelos de Matos; Leonor Fernandes; Maria Teresa Neves; Fátima Alves; Mafalda Baleiras; André Ferreira; Pedro Giesteira Cotovio; Tiago Dias Domingues; Mariana Malheiro; Ana Plácido; Maria Helena Miranda; Ana Martins
Journal:  Curr Oncol       Date:  2021-02-26       Impact factor: 3.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.